Compare Dyne Therapeutics Inc. Common Stock (DYN) vs TKO Group Holdings Inc (TKO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs TKO Group Holdings Inc — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.06 (market cap $2.86B), while TKO Group Holdings Inc trades at $173.56 (market cap $12.71B). The key difference: TKO Group Holdings Inc is far larger — about 4.4× Dyne Therapeutics Inc. Common Stock's market cap, and TKO Group Holdings Inc pays a 1.82% dividend while Dyne Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and TKO Group Holdings Inc for 31 Days on average.
| DYN | TKO | |
|---|---|---|
Market Cap | $2.86B | $12.71B |
Volume | 3,341,579 | 835,872 |
Sector | Health | Media |
52-Week High | $26.78 | $224.96 |
52-Week Low | $14.60 | $172.38 |
Typical Hold Time | 0 Days | 31 Days |
Enterprise Value | $2.18B | $17.07B |
Dividend Yield | — | 1.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
TKO trades at $173.86, near a 52-week low, with a bearish technical signal. The company reported mixed Q2 2026 earnings, missing EPS estimates but raising full-year guidance. Revenue growth is solid, with 2026 projected at $5.3B, though profitability remains modest with a net margin of 4.33%. Analyst sentiment is overwhelmingly positive, with a consensus price target of $227.00 and 89% buy ratings, but recent institutional selling and technical weakness suggest near-term caution.
The outlook is cautiously optimistic; strong media rights and franchise value underpin long-term growth, but high valuation multiples and recent price decline highlight execution risks. Investors should weigh robust analyst confidence against technical bearishness and margin pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About TKO Group Holdings Inc
TKO Group Holdings is a premium sports and entertainment company that serves as the parent entity for the Ultimate Fighting Championship (UFC) and World Wrestling Entertainment (WWE). Formed through a seismic merger orchestrated by Endeavor, TKO leverages a combined global fanbase of over 1 billion to drive massive revenue through media rights, global live events, and a unified sponsorship platform, effectively monopolizing the professional combat sports landscape.
Read more on TKO →
